alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsMission Advantages of Constant Power, Variable Isp Electrostatic ThrustersElectric propulsion has moved from station-keeping capability for spacecraft to primary propulsion with the advent of both the Deep Space One asteroid flyby and geosynchronous spacecraft orbit insertion. In both cases notably more payload was delivered than would have been possible with chemical propulsion. To provide even greater improvements electrostatic thruster performance could be varied in specific impulse, but kept at constant power to provide better payload or trip time performance for different mission phases. Such variable specific impulse mission applications include geosynchronous and low earth orbit spacecraft stationkeeping and orbit insertion, geosynchronous reusable tug missions, and interplanetary probes. The application of variable specific impulse devices is shown to add from 5 to 15% payload for these missions. The challenges to building such devices include variable voltage power supplies and extending fuel throughput capabilities across the specific impulse range.Document ID20010016102Acquisition SourceGlenn Research CenterDocument TypePreprint (Draft being sent to journal)AuthorsOleson, Steven R.*(NASA Glenn Research Center Cleveland, OH United States)*Date AcquiredSeptember 7, 2013Publication DateNovember 1, 2000Subject CategorySpacecraft Propulsion And PowerReport/Patent NumberNASA/TM-2000-210477AIAA Paper 2000-3413NAS 1.15:210477E-12473Meeting InformationMeeting: Joint PropulsionLocation: Huntsville, ALCountry: United StatesStart Date: July 16, 2000End Date: July 19, 2000Sponsors:American Inst. of Aeronautics and Astronautics,American Society for Electrical Engineers,Society of Automotive Engineers, Inc.,American Society of Mechanical EngineersFunding Number(s)PROJECT: RTOP 632-6B-1CDistribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType20010016102.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Viral Immunity.                     

*Date:*                         March 31, 2010.                    

*Time:*                         12:30 p.m. to 4:30 p.m.                              ( print page 10296)    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).                    

*Contact Person:*                         Betty Poon, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616, 301-451-2660,                         *poonb@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: March 1, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4751 Filed 3-4-10; 8:45 am]

BILLING CODE 4140-01-P
Attachment 4 

Industry Position Papers: 

API/NPRA/WSPA Flare Sulfur Analyzer RATA Testing Position 11-19-09 

API/NPRA/WSPA Flare Seal Monitoring Position 11-19-09 
API/NPRA/WSPA Flare Sulfur Analyzer RATA Testing Position 11-19-09

Subpart Ja requires Relative Accuracy Test Audits (RATAs) of the flare sulfur monitors because 

it applies Appendix F requirements to these monitors. RATA testing flares is problematic for the 

following reasons. 

1. Sources will be required to bypass flare gas recovery or route process or fuel gas to 

the flare and do significant flaring in order to provide the required representative samples 

for the RATA tests. Significant, unnecessary VOC, SO2 and NOx emissions will result. 

2. There is a potential safety risk to sampling personnel, should an emergency flaring 

event occur while they are sampling the flare header. While flare headers are normally at 

low pressures, backpressure can be significant during flaring events and exposure to 

toxics and potentially fire risk is a concern if an event occurs during RATA testing. The 

concern is amplified by the fact that in many cases these samples must be taken at 

difficult to access locations, making emergency escape difficult. 

3. Because flares typically can receive gas from many different sources, with widely 

varying compositions and sulfur contents, the flare sulfur monitors will have to cover a 

broad range and deal with very different gas compositions. It will therefore be difficult to 

generate “representative” samples for RATA testing from individual refinery streams. 

4. Under some State rules, Consent Decrees and permits, flaring is only permitted during 

certain conditions and the on-purpose RATA testing flaring would be construed as 

violating these conditions without regulatory revisions. 

These concerns have been addressed in California by allowing Cylinder Gas Audits in place of 

the RATA tests for these analyzers and we recommend the Agency do the same in Subpart Ja. 
Page 1 

API/NPRA/WSPA Flare Seal Monitoring Position 11-19-09

NSPS Ja requires flare gas flow monitoring. API/NPRA/WSPA recommended use of flare seal 

monitoring as an alternate to flow monitoring in certain situations. In gathering data to support 

that request, we have also found that flare seal monitoring can be important for eliminating false 

flow monitor readings on some flares. This is based on the logic that if the flare seal is not 

breached, then there is no flow to the flare from upstream of the flare seal. 

Experience in California shows that flare gas flow monitors can indicate a flow even where there 

is none. This is presumably an artifact of the detection limit of the measurement technology. In 

large flare headers, even a very low indicated flow can cause the RCA trigger for sulfur dioxide 

to be incorrectly exceeded. SCAQMD and BAAQMD have accepted flare seal monitoring (level 

and ΔP) as proof of false positive flare gas flow monitor readings. 

We therefore now request that flare drum seal monitoring be allowed as a voluntary supplement 

to the required gas flow monitoring.
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.3310 Hearing aid calibrator and analysis system. ( a ) *Identification.* A hearing aid calibrator and analysis system is an electronic reference device intended to calibrate and assess the electroacoustic frequency and sound intensity characteristics emanating from a hearing aid, master hearing aid, group hearing aid or group auditory trainer. The device consists of an acoustic complex of known cavity volume, a sound level meter, a microphone, oscillators, frequency counters, microphone amplifiers, a distoration analyzer, a chart recorder, and a hearing aid test box.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 874.9.
[51 FR 40389, Nov. 6, 1986, as amended at 84 FR 71813, Dec. 30, 2019]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AND THED STATEMENTS OF REVENUE AND EXPENSES AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH REPORT ON FORM 10-Q
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                       1,798,443
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               1,933,818
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   1,922,936
<TOTAL-LIABILITY-AND-EQUITY>                 1,933,618
<SALES>                                              0
<TOTAL-REVENUES>                               403,570
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                58,142
<LOSS-PROVISION>                               (6,949)
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (115,338)
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF HARBINGER CORPORATION FOR THE YEAR ENDED
DEC-31-1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH CONSOLIDATED
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          12,934
<SECURITIES>                                    60,086
<RECEIVABLES>                                   52,430
<ALLOWANCES>                                     8,455
<INVENTORY>                                          0
<CURRENT-ASSETS>                               123,919
<PP&E>                                          56,631
<DEPRECIATION>                                  30,292
<TOTAL-ASSETS>                                 169,459
<CURRENT-LIABILITIES>                           44,685
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             4
<OTHER-SE>                                     124,770
<TOTAL-LIABILITY-AND-EQUITY>                   169,459
<SALES>                                         46,841
<TOTAL-REVENUES>                               155,514
<CGS>                                            4,555
<TOTAL-COSTS>                                   50,997
<OTHER-EXPENSES>                                91,887
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 16,017
<INCOME-TAX>                                       813
<INCOME-CONTINUING>                             15,204
<DISCONTINUED>                                   1,356
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    16,560
<EPS-BASIC>                                       0.43
<EPS-DILUTED>                                     0.41


</TABLE>
Electronically Filed Intermediate Court of Appeals CAAP-18-0000505 15-JUL-2019 08:04 AM
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the balance
sheets and statements of operations found on page 2 and 4 of the Company's Form
10-Q for the year to date, and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<PERIOD-TYPE>                    3-MOS
<FISCAL-YEAR-END>                         DEC-31-1998
<PERIOD-END>                              MAR-31-1999
<CASH>                                    1,628,804
<SECURITIES>                                951,878
<RECEIVABLES>                             1,040,290
<ALLOWANCES>                                      0
<INVENTORY>                               1,004,248
<CURRENT-ASSETS>                          5,433,442
<PP&E>                                    4,722,947
<DEPRECIATION>                                    0
<TOTAL-ASSETS>                           10,660,327
<CURRENT-LIABILITIES>                       444,213
<BONDS>                                           0
<COMMON>                                  9,760,214
<PREFERRED-MANDATORY>                             0
<PREFERRED>                                       0
<OTHER-SE>                                    3,106
<TOTAL-LIABILITY-AND-EQUITY>             10,660,327
<SALES>                                   2,540,873
<TOTAL-REVENUES>                          2,540,873
<CGS>                                     1,685,363
<TOTAL-COSTS>                             1,685,363
<OTHER-EXPENSES>                            925,429
<LOSS-PROVISION>                                  0
<INTEREST-EXPENSE>                                0
<INCOME-PRETAX>                             (41,185)
<INCOME-TAX>                                (16,474)
<INCOME-CONTINUING>                         (24,711)
<DISCONTINUED>                                    0
<EXTRAORDINARY>                                   0
<CHANGES>                                         0
<NET-INCOME>                                (24,711)
<EPS-PRIMARY>                                  (.01)
<EPS-DILUTED>                                  (.01)

</TABLE>
mack-ex107_315.htm



Exhibit 10.7

 

April 3, 2017

Dear Jeff,

Merrimack Pharmaceuticals, Inc. (“Merrimack”) is pleased to provide you a one-time retention bonus of $350,000 (the “Retention Bonus”), less all applicable taxes and withholdings.  A portion of the Retention Bonus is considered an advance and is not earned unless you remain continuously employed and in good standing with Merrimack based on the following terms: (i) if you terminate your employment with Merrimack on or before December 31, 2017 without Good Reason (as defined in your Employment Agreement) or Merrimack terminates your employment on or before December 31, 2017 for Cause (as defined in your Employment Agreement), you shall be required to repay $233,333.33 of the Retention Bonus, minus any applicable taxes and withholdings that you were required to pay with respect to such amount, within 60 days after your termination, and (ii) if you terminate your employment with Merrimack on or after January 1, 2018 but on or before June 30, 2018 without Good Reason or Merrimack terminates your employment on or after January 1, 2018 but on or before June 30, 2018 for Cause, you shall be required to repay $116,666.67 of the Retention Bonus, minus any applicable taxes and withholdings that you were required to pay with respect to such amount, within 60 days after your termination, in each case, to the maximum extent permitted by applicable law.  You shall not be required to repay any portion of the Retention Bonus if you terminate your employment with Merrimack at any time for Good Reason or if Merrimack terminates your employment at any time without Cause.

This letter contains all of the understandings and representations between Merrimack and you relating to the Retention Bonus and supersedes all prior understandings, representations and agreements with respect to any retention bonus payments.  The opportunity for you to receive the Retention Bonus under the terms set forth in this letter shall not be construed as a guarantee of employment for any specific period of time, and your employment shall remain at-will.

We are excited to continue working with you.  If the terms set forth in this letter are acceptable to you, please sign this letter and return it to me.  If you have any questions do not hesitate to reach out. 

 


	
	
Best regards,

	
 

	
/s/ Shelley Phelps

	
Shelley Phelps, Talent Team

	
 

	
Accepted and Agreed:

	
 

	
/s/ Jeffrey A. Munsie

	
Jeffrey A. Munsie
# C_2015398EN.01004802.xml

| 30.11.2015 | EN | Official Journal of the European Union | C 398/48 |
| --- | --- | --- | --- |

30.11.2015

EN

Official Journal of the European Union

C 398/48

---

Judgment of the General Court of 7 October 2015 — The Smiley Company v OHIM (Shape of a face with horns)

(Case T-242/14) (1)

1

((Community trade mark - Application for a three-dimensional Community trade mark - Shape of a face with horns - Absolute ground for refusal - Distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009))

(2015/C 398/61)

Language of the case: English

Parties

Parties

Applicant: The Smiley Company SPRL (Brussels, Belgium) (represented by: A. Freitag and C. Albrecht, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: P. Geroulakos and A. Folliard-Monguiral, acting as Agents)

Defendant:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 16 January 2014 (Case R 836/2013-1) concerning an application for registration as a Community trade mark of a three-dimensional sign comprising the shape of a face with horns.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Annuls the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) of 16 January 2014 (Case R 836/2013-1) with regard to the refusal to register the mark applied for in respect of ‘preserved, frozen, dried and cooked fruits and vegetables; milk products’; |
| --- | --- |

1.

Annuls the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) of 16 January 2014 (Case R 836/2013-1) with regard to the refusal to register the mark applied for in respect of ‘preserved, frozen, dried and cooked fruits and vegetables; milk products’;

| 2. | Dismisses the action as to the remainder; |
| --- | --- |

2.

Dismisses the action as to the remainder;

| 3. | Orders the parties to bear their own costs. |
| --- | --- |

3.

Orders the parties to bear their own costs.

---

(1)  OJ C 282, 25.8.2014.

1

---
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5230 Colostrum immunological test system. ( a ) *Identification.* A colostrum immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the specific proteins in colostrum. Colostrum is a substance excreted by the mammary glands during pregnancy and until production of breast milk begins 1 to 5 days after childbirth.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 59 FR 63007, Dec. 7, 1994; 66 FR 38793, July 25, 2001]
Exhibit 32.2

CERTIFICATION PURSUANT TO
SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as
Chief Financial Officer of The Timberland Company (the "Company"), does hereby certify that to the undersigned's knowledge:



| |  |  | /s/BRIAN P. MCKEONBrian P. McKeon
Chief Financial Officer
| |  |  | ---------------------------------------------------------

Date:
November 10, 2004

The
foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of
Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A
signed original of this written statement, required by Section 906, has been provided to The Timberland Company and will be retained by The Timberland Company and furnished to the Securities
and Exchange Commission or its staff upon request.

---



QuickLinks